Occupation or Discipline
Novo Nordisk Invests $1.2 Billion in Rare Disease Production Facility in Denmark, Creating 400 New Jobs
Novo Nordisk, rare disease production, Denmark, new facility, job creation, pharmaceutical industry
SIGA’s TPOXX Fails to Demonstrate Efficacy in Treating Mild to Moderate Mpox Cases: STOMP Study Results
SIGA Technologies, TPOXX, Tecovirimat, Mpox, STOMP Study, Antiviral Treatment, Efficacy, Safety Profile
BenevolentAI Embarks on Strategic Overhaul to Realign with Founding TechBio Mission
BenevolentAI, strategic overhaul, TechBio mission, artificial intelligence, biopharmaceutical development, drug discovery, Kenneth Mulvany
Dimension Secures $500M for Second Fund, Focusing on the Intersection of Science and Technology
Dimension, Venture Capital, Science, Technology, Biotech, AI, Machine Learning, Life Sciences, Innovation
Eli Lilly Invests $3 Billion in Wisconsin Manufacturing Expansion to Meet Growing Demand for Diabetes and Obesity Medicines
Eli Lilly, Wisconsin, manufacturing expansion, diabetes, obesity, pharmaceuticals, investment, job creation
Lil Jon Teams Up with Singing Toilet for Unconventional Cancer Awareness Campaign
Lil Jon, scat rap, singing toilet, Exact Sciences, cancer kit, promotional campaign
Kinevant Sciences Discontinues Namilumab Development for Pulmonary Sarcoidosis Following Phase 2 Failure
Namilumab, Pulmonary Sarcoidosis, Phase 2 Study, Kinevant Sciences, RESOLVE-Lung Study, Anti-GM-CSF Monoclonal Antibody
Ipsen and Biomunex Partner on First-in-Class MAIT Cell Engager for Solid Tumors in $610M Deal
Ipsen, Biomunex, MAIT cell engager, T cell engager, solid tumors, immuno-oncology, BMX-502, BiXAb technology, GPC3 tumor antigen.
Novartis Announces 139 Job Cuts in New Jersey Amid Commercial Refocus
Novartis, job cuts, New Jersey, commercial refocus, restructuring
Embecta Discontinues Insulin Patch Pump Program Amid Restructuring Efforts
Embecta, insulin patch pump, discontinuation, restructuring, layoffs, diabetes technology